In clinical trials based on 655 patients with partial-onset seizures, XCOPRI reduced median seizure frequency by 8.5 seizures for an average of 24 years.
XCOPRI Reduces Number Of Partial-Onset Seizures In Adults, Earns FDA Approval
In clinical trials based on 655 patients with partial-onset seizures, XCOPRI reduced median seizure frequency by 8.5 seizures for an average of 24 years.